Barron's seventh annual (2024) ranking of Sustainable companies started with the 1,000 largest publicly traded companies by market value, then ranked each by performance for five key constituencies: shareholders, employees, customers, community, and planet. Home-products company Clorox sits at the top for the second straight year, edging out Kimberly-Clark, CBRE Group, Hasbro, and Agilent Technologies in the top five. Per 8/8/24 data from YCharts, the top-10 of 77 dividend-paying sustainable companies ranged 4.34%-14.68% by annual yield and ranged 31.29%-79.66% by broker-estimated target-price upsides.

On Friday, Merck & Co Inc MRK agreed to acquire CN201, an investigational clinical-stage bispecific antibody for B-cell-associated diseases, from privately-held Curon Biopharmaceutical.

Merck said Friday it's has agreed to acquire an experimental drug targeting B-cell associated diseases for up to $1.3 billion.

Merck (MRK) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Merck & Co. MRK, +1.21% said Thursday it's discontinuing a late-stage trial of a treatment for patients with extensive-stage small cell lung cancer after patients experienced a high rate of adverse events. The company said it's notifying study investigators of the decision and telling them patients should stop treatment, which was a fixed dose of vibostolimab, an anti-TIGIT antibody, and pembrolizumab, or Keytruda, Merck's blockbuster cancer drug, in combination with chemotherapy compared to atezolizumab in combination with chemotherapy.

Merck said on Thursday it had discontinued its trial of a combination of its experimental drug and blockbuster therapy Keytruda for the treatment of a type of lung cancer, after an interim analysis showed the drug was unlikely to succeed.

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Update on Phase 3 KeyVibe-008 Trial Evaluating Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With ES-SCLC.

Amid the stock market turmoil, wagering on the best biotech stocks could be a savvy move. The stock market has been tumultuous lately, which could spur a pivot toward defensive biotech stocks.

Merck is finding ways to avoid a fast-approaching patent cliff by continuing to do what it's done for a while. Medtronic is a diversified healthcare giant with several important long-term growth catalysts.

Goldman Sachs recently discussed with Joe Romanelli, President of Human Health International at Merck & Co Inc MRK, to review Gardasil's performance and future outlook in China.

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes?

Merck fell as it cut its guidance and performance from its HPV drug disappointed. Microsoft delivered a solid earnings report, but it wasn't good enough for the market.